心肌梗塞的体外生命支持:新的亮点
Giulia Piccone1, Lorenzo Schiavoni2, Alessia Mattei2
1Cardiothoracic and Vascular Intensive Care Unit, Hospital and University Trust of Verona, P. le A. Stefani, 37124 Verona, Italy.
Medicina (Kaunas, Lithuania)
|June 27, 2024
概括
静脉动脉外体膜氧化 (VA-ECMO) 在心肌梗塞后心脏性休克中使用显示出混合的结果. 目前的证据并不普遍支持常规VA-ECMO,因为风险和数据有限,需要进一步的试验.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 医疗技术 医疗技术 医学技术
背景情况:
- 心脏性休克 (CS) 是急性心肌梗塞 (AMI) 的严重并发症.
- 静脉动脉外体膜氧化 (VA-ECMO) 的使用在耐火性CS中增加了.
- 在AMI复杂的CS中VA-ECMO的证据正在发展,需要更新的审查.
研究的目的:
- 审查VA-ECMO在CS复杂化AMI的作用和最近的文献.
- 突出临床结果,断奶策略和VA-ECMO治疗中的新兴趋势.
主要方法:
- 对VA-ECMO在AMI中的CS实践的文献综述.
- 专注于2019年至2024年在PubMed.Med上发表的研究.
- 包括报告显著临床结果和断奶数据的最大研究.
主要成果:
- 早期的文献包括观察性研究;随机对照试验 (RCT) 现在正在出现.
- 风险试验 (EURO-SHOCK,ECMO-CS,ECLS-SHOCK) 显示VA-ECMO对死亡率有不同的或没有显著的好处.
- 与左心室卸载装置的联合治疗显示出潜在的可能性,但增加了并发症率.
结论:
- 由于证据和风险不足,用于CS的AMI的常规VA-ECMO并未得到普遍支持.
- 标准化机械循环支持 (MCS) 的时间和指示对于未来的研究至关重要.
- 个性化,多学科的方法对于优化患者护理和最大限度地减少MCS并发症至关重要.
相关概念视频
01:17Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
01:30Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
01:22Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
01:30Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
01:29Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753